Pharmaceuticals
ASCO 2021 | Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation
SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts reporting on t...
2021-05-20 08:17
5909
Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies
SUZHOU, China, May 20, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) d...
2021-05-20 08:00
2919
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
* Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages * Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has...
2021-05-20 06:00
8729
Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
SUZHOU, China and PALO ALTO, Calif., May 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated ...
2021-05-20 05:15
9050
Eurofins Discovery Launches Human Immune Models for COVID-19 New Therapeutic Discovery or Repurposing
ST. CHARLES, Mo., May 18, 2021 /PRNewswire/ -- Eurofins Discovery, the market leader in pharmacology services and drug discovery products with over forty years providing solutions for the pharmaceutical and biotech industry, announces the launch of new services in support of clients working to ad...
2021-05-18 21:00
2139
Atonarp Announces $50M Series D Financing to Scale its Molecular Sensing and Digital Diagnostics Testing Platforms
Michael Marks, Founding Partner for WRVI Capital, Joins the Atonarp Board and Former Berkeley Lights CFO Shaun Holt Joins as Atonarp's Chief Operating Officer TOKYO, May 18, 2021 /PRNewswire/ -- Atonarp, a leading manufacturer of molecular sensing and diagnostics products for the healthcare, phar...
2021-05-18 18:00
3517
Nanoform's final clinical results confirm value proposition to the pharma industry
HELSINKI, Finland, May 18, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform "), an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study. The primary, secondary and optional exploratory objectives of the study were all met. Th...
2021-05-18 13:48
1518
U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, May 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in...
2021-05-18 12:14
13361
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
* The publication is available as a pre-print on bioRxiv * Preclinical data demonstrates that a modified B.1.351 S-Trimer vaccine candidate induces broad neutralization against both the original SARS-CoV-2 strain and variants of concern (VoC) including the South African variant * A single bo...
2021-05-18 11:50
3324
Farrer Park Hospital Elevates Cancer Care with PIPAC Treatment for Late to End-stage Cancer Patients
SINGAPORE, May 18, 2021 /PRNewswire/ -- Farrer Park Hospital
2021-05-18 08:15
2362
EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines
PROVIDENCE, R.I., May 17, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation" in NPJ Vaccines. This research identifies peptide epitopes associated with T...
2021-05-17 20:54
2620
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
Dr. Dansey, Seagen's Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board's diverse industry, clinical development, research and commercialization expertise PLYMOUTH MEETING, Pa., May 17, 20...
2021-05-17 20:00
4833
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, May 17, 2021 /PRNewswire/ -- Everest Medicines
2021-05-17 16:51
4306
Nippon Express (China) Becomes First Japanese Company to Acquire GDP Certification in China
TOKYO, May 17, 2021 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NE China"), a local subsidiary of Nippon Express Co., Ltd., has obtained Good Distribution Practice (GDP) certification, effectiveMonday, March 29, 2021, for its Shanghai Pudong Airport CFS, making it the first Jap...
2021-05-17 15:00
4523
Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2021-05-17 09:00
5152
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onc...
2021-05-17 08:00
3568
Luye Life Sciences Unveils Cutting-edge Advances in Gene and Cell Therapy at ASGCT 2021
BOSTON, May 13, 2021 /PRNewswire/ -- The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company's latest preclinical developments in ...
2021-05-14 11:58
2706
Final Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for Acute Promyelocytic Leukaemia (APL) Confirm Bioequivalence of Oral and IV Formulations
SYDNEY, May 13, 2021 /PRNewswire/ -- Australian pharmaceutical group Phebra (' Company') congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initi...
2021-05-14 10:33
1472
Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-05-14 08:40
4905
I-Mab Added to MSCI China Index
SHANGHAI and GAITHERSBURG, Md., May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab has been selected for inclusion in the MSCI Ch...
2021-05-13 20:00
5466
Week's Top Stories
Most Reposted
UFO SIM Launches in Australia, The Ultimate Travel eSIM Starting at Just AU$2/GB
[Picked up by 310 media titles]
2026-04-01 11:03
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements
[Picked up by 305 media titles]
2026-04-01 09:00
From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 302 media titles]
2026-03-31 13:53
DayOne Announces RM28+ Billion Commitment and Talent Initiatives in Malaysia at Inaugural Tech & AI Career Expo
[Picked up by 291 media titles]
2026-04-01 22:23
Most Read
Herbalife to Expand Its Personalized Nutritional Supplement Capabilities Through Planned Acquisition of Bioniq
2026-03-30 12:00
6139
